INanoBio Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 17
Employees
  • Latest Deal Type
  • Grant
  • (Announced)
  • Latest Deal Amount
  • $5.4M
Latest Deal Amount
  • Investors
  • 1

INanoBio General Information

Description

Developer of an advanced 3D field-effect nanopore transistor (FENT) device intended for sequencing the whole human genome. The company's device is based on CMOS semiconductor nanotechnology and will be over 100 times faster than protein nanopore-based sequencers, enabling medical professionals to perform genomic analysis with high accuracy, at less than one-tenth the current cost and time.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Electronic Equipment and Instruments
Primary Office
  • 7201 East Henkel Way
  • Suite 285
  • Scottsdale, AZ 85255
  • United States
+1 (602) 000-0000

INanoBio Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

INanoBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 01-Apr-2019 $5.4M 00.00 Announced Product Development
8. Seed Round 23-Dec-2020 00.00 00.00 Completed Product Development
7. Debt - PPP 28-Apr-2020 00.000 Completed Product Development
6. Seed Round 06-Feb-2020 00.00 00.000 Completed Product Development
5. Grant 30-Sep-2019 00000 00.000 Completed Product Development
4. Seed Round 09-Oct-2018 000 00.000 Completed Product Development
3. Angel (individual) 05-Apr-2016 00000 00000 Completed Product Development
2. Angel (individual) 22-Jun-2017 Completed Startup
1. Grant 05-Jan-2012 $330K Completed Startup
To view INanoBio’s complete valuation and funding history, request access »

INanoBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an advanced 3D field-effect nanopore transistor (FENT) device intended for sequencing the whole human genom
Diagnostic Equipment
Scottsdale, AZ
17 As of 2021
00.00
0000000000 00.00

000000 0

por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000000000 000000000 000 00000000000
Oxford, United Kingdom
000 As of 0000
00.000
0.000 0000-00-00
00000000 00.000

00000000

, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000000000 000000000
Redwood City, CA
000 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

INanoBio Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Nanopore Technologies Formerly VC-backed Oxford, United Kingdom 000 00.000 00000000 00.000
00000000 Venture Capital-Backed Redwood City, CA 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Menlo Park, CA 000 00000 000000000 00000
00000000 Formerly VC-backed San Diego, CA 0000 00000 000000&0
To view INanoBio’s complete competitors history, request access »

INanoBio Patents

INanoBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3717909-A1 Field effect transistor sensor detection assays and systems and methods of making and using same Pending 28-Nov-2017 000000000000
US-20200386751-A1 Field effect transistor sensor detection assays and systems and methods of making and using same Pending 28-Nov-2017 000000000000
EP-3698136-A1 Disease proteome protein arrays and uses thereof Pending 16-Oct-2017 000000000000
EP-3698136-A4 Disease proteome protein arrays and uses thereof Pending 16-Oct-2017 000000000000 0
US-20200309773-A1 Disease proteome protein arrays and uses thereof Pending 16-Oct-2017 G01N33/54366

INanoBio Executive Team (8)

Name Title Board Seat Contact Info
Bharath Takulapalli Ph.D Founder, Chief Executive Officer & Board Member
Mukilan Mohan Co-Founder, Chief Operating Officer & Board Member
George Church Ph.D Scientific Advisor
Thomas Hoster Consulting Chief Financial Officer
Chenming Hu Ph.D Member of Scientific Advisory Board
You’re viewing 5 of 8 executive team members. Get the full list »

INanoBio Board Members (5)

Name Representing Role Since
Abhay Sanan INanoBio Board Member & Scientific Advisor 000 0000
Bharath Takulapalli Ph.D INanoBio Founder, Chief Executive Officer & Board Member 000 0000
George Poste Ph.D Self Board Member & Scientific Advisor 000 0000
Jean-Pierre Millon INanoBio Board Member 000 0000
Mukilan Mohan INanoBio Co-Founder, Chief Operating Officer & Board Member 000 0000
To view INanoBio’s complete board members history, request access »

INanoBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

INanoBio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
The National Human Genome Research Institute Government 000 0000 000000 0
To view INanoBio’s complete investors history, request access »